1. Scrip
  2. >>Business
  3. >>Financing

Clasp Launches With $150m To Develop Personalized T-Cell Engagers

Dual Agents Target Oncogenes And HLA Proteins

 
• By Mandy Jackson

Clasp Therapeutics, which emerged from labs at Johns Hopkins University and was incubated by a pair of venture capital investors, plans to achieve a clinical trial readout with its series A cash.

Start-up Funding Crowdfunding Investment Venture Capital Entrepreneurship Internet Business Technology Concept
Clasp will take at least one candidate into the clinic with its new funding • Source: Shutterstock

Clasp Therapeutics is developing next-generation T-cell engagers with the aim of developing off-the-shelf immuno-oncology therapeutics that have precise tumor targeting with limited on-target, off-tumor adverse events. And now with a $150m series A venture capital round announced on 20 March, the company plans to develop its first therapeutic candidates from preclinical all the way through initial clinical trial data.

Key Takeaways

  • Clasp Therapeutics launched with a $150m series A round to develop off-the-shelf T-cell engagers based on research conducted at Johns Hopkins University.

Cambridge, MA- and Rockville, MD-based Clasp emerged from the labs of cancer genetics specialist Bert Vogelstein and immuno-oncology researcher Drew...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

BIO Notebook: IPO Window Stays Shut, PRVs Need To Be A Priority, And Focusing On Gene Therapy Safety

 
• By Mandy Jackson and Sarah Karlin-Smith

Highlights from day one of the BIO convention include advice for firms hoping to go public, a call for companies to push the US Congress on rare disease priority review vouchers, and updates on next-generation gene therapies.

Finance Watch: Scorpion Spinout Antares Launches With $177m For Precision Medicines

 
• By Mandy Jackson

Private Company Edition: Antares’ lead asset will enter the clinic in 2026 after Lilly committed up to $2.5bn for Scorpion’s Phase I/II PI3Kα inhibitor STX-478. Also, Amplify raised $200m for its first biotech VC fund and Mosanna raised an $80m series A round, among other financings.

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering

 
• By Mandy Jackson

Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

More from Business

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.